⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MTVA News
MetaVia Inc. Common Stock
Form 8-K
sec.gov
MTVA
MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity
prnewswire.com
MTVA
Form 8-K
sec.gov
MTVA
Form 8-K
sec.gov
MTVA
MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update
prnewswire.com
MTVA
Form 8-K
sec.gov
MTVA
MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control
prnewswire.com
MTVA
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
globenewswire.com
JUNS
DYAI
PHIO
CVKD
TNXP
MTVA
XAIR
AEMD
NSRX
ICU
JAGX
MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035
prnewswire.com
MTVA
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum
prnewswire.com
MTVA